$2.67 Billion is the total value of PFM Health Sciences, LP's 68 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | GILEAD SCIENCES INCcall | $83,973,000 | – | 1,412,500 | +100.0% | 3.14% | – | |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $80,389,000 | – | 516,406 | +100.0% | 3.01% | – |
| BDX | New | BECTON DICKINSON & CO | $41,920,000 | – | 157,593 | +100.0% | 1.57% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $34,066,000 | – | 1,062,888 | +100.0% | 1.27% | – |
| CI | New | CIGNA CORP NEW | $22,556,000 | – | 94,135 | +100.0% | 0.84% | – |
| QURE | New | UNIQURE NV | $9,661,000 | – | 534,624 | +100.0% | 0.36% | – |
| VERV | New | VERVE THERAPEUTICS INC | $8,438,000 | – | 369,765 | +100.0% | 0.32% | – |
| CCCC | New | C4 THERAPEUTICS INC | $6,909,000 | – | 284,772 | +100.0% | 0.26% | – |
| GBIO | New | GENERATION BIO CO | $4,215,000 | – | 574,278 | +100.0% | 0.16% | – |
| SANA | New | SANA BIOTECHNOLOGY INC | $2,935,000 | – | 355,272 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLINA HEALTHCARE INC | 41 | Q3 2023 | 2.2% |
| HCA HOLDINGS INC | 38 | Q3 2023 | 5.2% |
| HUMANA INC | 37 | Q3 2023 | 3.8% |
| EDWARDS LIFESCIENCES CORP | 36 | Q3 2023 | 3.3% |
| UNITEDHEALTH GROUP INC | 33 | Q3 2023 | 4.8% |
| PENUMBRA INC | 33 | Q3 2023 | 4.8% |
| AERIE PHARMACEUTICALS INC | 28 | Q2 2022 | 3.7% |
| TENET HEALTHCARE CORP | 27 | Q3 2023 | 2.3% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 4.2% |
| ICON PLC | 26 | Q3 2023 | 2.5% |
View PFM Health Sciences, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adaptimmune Therapeutics PLC | February 14, 2023 | ? | ? |
| Arcus Biosciences, Inc. | February 14, 2023 | ? | ? |
| Axsome Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Erasca, Inc. | February 14, 2023 | ? | ? |
| Generation Bio Co. | February 14, 2023 | ? | ? |
| IO Biotech, Inc. | February 14, 2023 | ? | ? |
| Jounce Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Outset Medical, Inc. | February 14, 2023 | ? | ? |
| uniQure N.V. | February 14, 2023 | ? | ? |
| AERIE PHARMACEUTICALS INC | February 14, 2022 | ? | ? |
View PFM Health Sciences, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-21 |
View PFM Health Sciences, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.